Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?

scientific article

Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2014PLoSO...990153W
P356DOI10.1371/JOURNAL.PONE.0090153
P932PMC publication ID3940848
P698PubMed publication ID24595218
P5875ResearchGate publication ID260527228

P2093author name stringHuan Wang
Yu Fu
Xiaohua Hou
Wei Qian
Jing Gong
Wenfeng Wang
Yanqin Long
Xiaochao Fu
P2860cites workPrevalence of irritable bowel syndrome: a community surveyQ24535897
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndromeQ33409756
Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndromeQ33421773
The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized studyQ33433775
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloatingQ33434046
Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?Q33443774
Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviewsQ33451712
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysisQ33457565
Probiotic treatment of irritable bowel syndrome in childrenQ33730572
A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndromeQ33955996
Probiotics: future directionsQ34274145
Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breveQ34706995
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndromeQ34731103
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic reviewQ34906850
Postinfectious irritable bowel syndromeQ34982123
AGA technical review on irritable bowel syndromeQ35010302
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection.Q35750853
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome.Q36160305
Preventive effect of glutamine on intestinal barrier dysfunction induced by severe traumaQ36309080
Meta-analysis of probiotics for the treatment of irritable bowel syndromeQ37156630
Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort studyQ37417328
Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.Q37444649
Th17: a new participant in gut dysfunction in mice infected with Trichinella spiralisQ37452755
Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria.Q37973803
VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover studyQ39286213
A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physiciansQ56883300
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profilesQ59880418
Spectrophotometric assay for D-(-)-lactate in plasmaQ71136665
Intestinal adherent bacteria and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infectionQ73484608
Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouseQ80440416
Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndromeQ84705462
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndromeQ39348241
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndromeQ39396709
The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban communityQ39684155
Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel SyndromeQ40306009
Tight junctions and the molecular basis for regulation of paracellular permeabilityQ40373935
Diamine oxidase: an overview of historical, biochemical and functional aspectsQ40760854
D-lactate production and excretion in diarrheic calvesQ42162214
Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndromeQ44520650
Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunctionQ44802880
Impact of Bifidobacterium bifidum MIMBb75 on mouse intestinal microorganismsQ46456070
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.Q48516420
Psychometric scores and persistence of irritable bowel after infectious diarrhoea.Q51117034
Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.Q53184076
Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome.Q53201131
Carbohydrates and Lipids in Trichinella spiralis Larvae and Their Utilization In vitroQ53780528
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)e90153
P577publication date2014-03-03
P1433published inPLOS OneQ564954
P1476titleAre there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?
P478volume9

Reverse relations

cites work (P2860)
Q47160578A Novel Prebiotic Blend Product Prevents Irritable Bowel Syndrome in Mice by Improving Gut Microbiota and Modulating Immune Response
Q38376282Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges
Q64065548Butyrate production in patients with end-stage renal disease
Q28817192Can probiotics modulate human disease by impacting intestinal barrier function?
Q55612911Dynamic changes in morphology, gene expression and microbiome in the jejunum of compensatory-growth rats induced by protein restriction.
Q90136095Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome
Q40610748Effect of probiotic bacteria on phagocytosis and respiratory burst activity of blood polymorphonuclear leukocytes (PMNL) in mice infected with Trichinella spiralis.
Q92318232Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model
Q35586987Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
Q55517435Fecal Microbiota Transplantation Is Effective in Relieving Visceral Hypersensitivity in a Postinfectious Model.
Q36040649Fermented Yupingfeng polysaccharides enhance immunity by improving the foregut microflora and intestinal barrier in weaning rex rabbits
Q42356646Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota
Q37289543Ginsenoside Rb1 protects the intestinal mucosal barrier following peritoneal air exposure
Q28085584Gut microbiota as potential orchestrators of irritable bowel syndrome
Q38815064Helminths and intestinal barrier function
Q36355131Isomalto-oligosaccharides ameliorate visceral hyperalgesia with repair damage of ileal epithelial ultrastructure in rats.
Q48313903Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress.
Q58590765Pharmacological Activation of PXR and CAR Down-regulates Distinct Bile Acid-metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis
Q40387665Piezo2: A Candidate Biomarker for Visceral Hypersensitivity in Irritable Bowel Syndrome?
Q41087764Preinduction of heat shock protein 70 protects mice against post-infection irritable bowel syndrome via NF-κB and NOS/NO signaling pathways
Q57465741Probiotic Clostridium butyricum Improves the Growth Performance, Immune Function, and Gut Microbiota of Weaning Rex Rabbits
Q41643040Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials.
Q58693647Qi-Deficiency Related Increases in Disease Susceptibility Are Potentially Mediated by the Intestinal Microbiota
Q57094367Seasonality of the gut microbiota of free-ranging white-faced capuchins in a tropical dry forest
Q41985685Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients
Q36340310Specific immunotherapy in combination with Clostridium butyricum inhibits allergic inflammation in the mouse intestine
Q38645789Starring role of toll-like receptor-4 activation in the gut-liver axis
Q51684544Study on the effects of microencapsulated Lactobacillus delbrueckii on the mouse intestinal flora.
Q34151572The effect of peritoneal air exposure on intestinal mucosal barrier
Q26739291The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments
Q87356652Thrombospondin 1 Modulates Monocyte Properties to Suppress Intestinal Mucosal Inflammation

Search more.